Recursion discreetly culls a rare disease program to focus on cancer, pulls in $150M private placement
Recursion Pharmaceuticals quietly shut down work on one of its clinical programs Tuesday.
Researchers will end development on REC-3599, a drug candidate for GM2 gangliosidosis, the Salt Lake City biotech said in SEC filings Tuesday. Recursion CEO Chris Gibson told Endpoints News that the move will help the company focus more on its oncology work.
“We were in a position where that program was going to read out very likely much, much later than any of the other programs in our pipeline,” Gibson said. “That meant that something had to come out of the funnel, and for us it was a program that’s further on the horizon.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
